{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:29:04Z","timestamp":1771561744048,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1016\/s1367-5931(99)80071-4","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T10:55:32Z","timestamp":1027594532000},"page":"489-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["New targets for anti-inflammatory drugs"],"prefix":"10.1016","volume":"3","author":[{"given":"Alan J","family":"Lewis","sequence":"first","affiliation":[]},{"given":"Anthony M","family":"Manning","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1367-5931(99)80071-4_reference0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM199901213400306","article-title":"Drug therapy: treatment of asthma with drugs modifying the leukotriene pathway","volume":"340","author":"Drazen","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/S1367-5931(99)80071-4_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib3","first-page":"211","article-title":"Biological insights from clinical trials with anti-TNF therapy","volume":"20","author":"Feldmann","year":"1998"},{"key":"10.1016\/S1367-5931(99)80071-4_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199901283400411","article-title":"Anticytokine therapy \u2014a new era in the treatment of rheumatoid arthritis","volume":"340","author":"O'Dell","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/S1367-5931(99)80071-4_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-199856030-00001","article-title":"The future role of anti-tumor necrosis factor-alpha products in the treatment of Crohn's disease","volume":"56","author":"Van Hogezand","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/S1367-5931(99)80071-4_bib6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"New Engl J Med"},{"key":"10.1016\/S1367-5931(99)80071-4_bib8","first-page":"203","article-title":"New treatments for arthritis","volume":"33","author":"Badger","year":"1998","journal-title":"Annu Rept Med Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib9","first-page":"241","article-title":"Agents that block TNF-\u03b1 synthesis or activity","volume":"32","author":"Black","year":"1997","journal-title":"Annu Rept Med Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.281.5379.1001","article-title":"Feedback inhibition of macrophage tumor necrosis factor-\u03b1 production by tristetraprolin","volume":"281","author":"Carballo","year":"1998","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80071-4_bib11","first-page":"2250","article-title":"Effects of murine recombinant interleukin 1 but not tumor necrosis factor in early cartilage damage in immune complex arthritis in mice","volume":"22","author":"Van de Loo","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0060","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arth Rheum"},{"key":"10.1016\/S1367-5931(99)80071-4_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen induced arthritis in DBAP\/1 mice: a comparative study using anti-TNF-\u03b1, IL-1\u03b11B, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arth Rheum"},{"key":"10.1016\/S1367-5931(99)80071-4_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1529-0131(199901)42:1<1::AID-ANR1>3.0.CO;2-4","article-title":"Review: gene therapy for rheumatic diseases","volume":"42","author":"Evans","year":"1999","journal-title":"Arth Rheum"},{"key":"10.1016\/S1367-5931(99)80071-4_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev.immunol.15.1.675","article-title":"Human chemokines: an update","volume":"15","author":"Baggiolini","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/33340","article-title":"Chemokines and leukocyte traffic","volume":"392","author":"Baggiolini","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1359-6446(98)01280-X","article-title":"Opportunities for novel therapeutic agents acting at chemokine receptors","volume":"4","author":"Saunders","year":"1999","journal-title":"Drug Discov Today"},{"key":"10.1016\/S1367-5931(99)80071-4_bib18","series-title":"Inflammation: Basic Principles and Clinical Correlates","article-title":"Agents targeting transcription factors","author":"Manning","year":"1999"},{"key":"10.1016\/S1367-5931(99)80071-4_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I","article-title":"Signal transduction and transcription factors in rheumatic disease","volume":"42","author":"Firestein","year":"1999","journal-title":"Arth Rheum"},{"key":"10.1016\/S1367-5931(99)80071-4_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s001090050063","article-title":"Transcription factor AP-1 regulation by mitogen-activated protein kinese signal transduction pathways","volume":"74","author":"Whitmarsh","year":"1996","journal-title":"J Mol Med"},{"key":"10.1016\/S1367-5931(99)80071-4_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0959-437X(94)90097-3","article-title":"Regulation of transcription by MAP kinase cascades","volume":"4","author":"Treisman","year":"1996","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/S1367-5931(99)80071-4_bib22","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/MCB.19.4.2435","article-title":"Mitogen-activated protein kinases: specific messages from ubiquitous messengers","volume":"4","author":"Schaeffer","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0955-0674(98)80143-9","article-title":"Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development","volume":"10","author":"Ip","year":"1998","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0968-0004(98)01309-7","article-title":"Structural organization of MAP kinase signaling modules by scaffold proteins in yeast and mammals","volume":"23","author":"Whitmarsh","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/S1367-5931(99)80071-4_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0955-0674(97)80068-3","article-title":"AP-1 function and regulation","volume":"9","author":"Karin","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib26","first-page":"865","article-title":"Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the JNK3 gene","volume":"389","author":"Yang","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0135","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1126\/science.282.5396.2092","article-title":"Defective T cell differentiation in the absence of JNK1","volume":"282","author":"Dong","year":"1998","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1074-7613(00)80640-8","article-title":"Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2","volume":"9","author":"Yang","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/S1367-5931(99)80071-4_bib29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1126\/science.270.5240.1326","article-title":"Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis","volume":"270","author":"Xia","year":"1995","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80071-4_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1359-6101(98)00011-2","article-title":"Pharmacological modulation of cytokine action and production through signaling pathways","volume":"9","author":"Young","year":"1998","journal-title":"Cyt Growth Factor Rev"},{"key":"10.1016\/S1367-5931(99)80071-4_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/emboj\/16.2.295","article-title":"Activation of stress activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK\/p38)","volume":"16","author":"Cuenda","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/S1367-5931(99)80071-4_bib32","doi-asserted-by":"crossref","first-page":"30122","DOI":"10.1074\/jbc.272.48.30122","article-title":"Characterization of the structure and function of the fourth member of p38 group mitogen \u2014activated protein kinase p38\u03b4","volume":"272","author":"Jiang","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0962-8924(97)01105-7","article-title":"The search for physiological substrates of MAP and SAP kinases in mammalian cells","volume":"7","author":"Cohen","year":"1997","journal-title":"Trends Cell Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0170","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase","volume":"273","author":"Favata","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0175","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1021\/bi972914c","article-title":"Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity","volume":"37","author":"Williams","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/S1367-5931(99)80071-4_bib36","doi-asserted-by":"crossref","first-page":"15605","DOI":"10.1074\/jbc.273.25.15605","article-title":"Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor SB203580, by alteration of one or more amino acids within the ATP binding pocket","volume":"273","author":"Gum","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1074-5521(97)90194-0","article-title":"The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase","volume":"4","author":"Wilson","year":"1997","journal-title":"Chem Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1074-5521(98)90170-3","article-title":"Conversion of SB 203580 insensitive MAP kinase family members to drugsensitive forms by a single amino acid substitution","volume":"5","author":"Eyers","year":"1998","journal-title":"Chem Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib39","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/S0960-894X(98)00495-8","article-title":"Pyrroles and other heterocycles as inhibitors of p38 kinase","volume":"8","author":"Hacker","year":"1998","journal-title":"J Bioorg Med Chem Lett"},{"key":"10.1016\/S1367-5931(99)80071-4_bib40","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1021\/jm980497b","article-title":"6-amino-2-(4-fluorophenyl) -4-methoxy-3- (4-pyridyl) -1H-pyrrolo[2,3-b]pyridine [RWJ68356]: a potent and selective p38 kinase inhibitor","volume":"41","author":"Henry","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib41","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/mend.11.9.9979","article-title":"Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo","volume":"11","author":"Vayssiere","year":"1997","journal-title":"Mol Endocrinol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/mend.13.2.0237","article-title":"Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun\/ C-Fos dimerization","volume":"13","author":"Zhou","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib43","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1101\/gad.11.24.3351","article-title":"Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway","volume":"11","author":"Caelles","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/S1367-5931(99)80071-4_bib44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-\u03baB, a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"New Engl J Med"},{"key":"10.1016\/S1367-5931(99)80071-4_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(08)60742-7","article-title":"NF-\u03baB as a frequent target for immunosuppressive and anti-inflammatory molecules","volume":"65","author":"Baeuerle","year":"1997","journal-title":"Adv Immunol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/41493","article-title":"A cytokine responsive I\u03baB kinase that activates the transcription factor NF-\u03baB","volume":"388","author":"DiDonato","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80071-4_bib47","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.278.5339.860","article-title":"IKK-1 and IKK-2: cytokine-activated i\u03bab kinases essential for NF-\u03baB activation","volume":"278","author":"Mercurio","year":"1997","journal-title":"Science"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0240","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/25159","article-title":"Identification of the receptor component of the I\u03baB\u03b1-ubiquitin ligase","volume":"396","author":"Yaron","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80071-4_reference0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1101\/gad.13.5.505","article-title":"A ubiquitin ligase complex essential for the NF-\u03baB, wart\/wingless, and hedgehog signaling pathways","volume":"13","author":"Maniatis","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/S1367-5931(99)80071-4_bib50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/385540a0","article-title":"MAP3K-related kinase involved in NF-\u03baB induction by TNF, CD95 and IL-1","volume":"385","author":"Malinin","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80071-4_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0092-8674(00)81842-5","article-title":"Activation of the IkB alpha complex by MEKK1, a kinase of the JNK pathway","volume":"88","author":"Lee","year":"1997","journal-title":"Cell"},{"key":"10.1016\/S1367-5931(99)80071-4_bib52","first-page":"233","article-title":"Kinases in pro-inflammatory signal transduction pathways: new opportunities for drug discovery","volume":"33","author":"Baichwal","year":"1998","journal-title":"Annu Rept Med Chem"},{"key":"10.1016\/S1367-5931(99)80071-4_bib53","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/MCB.19.3.2180","article-title":"Activation of IkappaB kinase beta by protein kinase C isoforms","volume":"19","author":"Lallena","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S1367-5931(99)80071-4_bib54","first-page":"429","article-title":"Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation","volume":"96","author":"Beraud","year":"1999"},{"key":"10.1016\/S1367-5931(99)80071-4_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of i\u03bab kinase-\u03b2","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1367-5931(99)80071-4_bib56","first-page":"2150","article-title":"Discovery and analysis of inflammatory disease-related genes using cDNA microarrays","volume":"94","author":"Heller","year":"1997"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593199800714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:13:51Z","timestamp":1761272031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593199800714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["S1367593199800714"],"URL":"https:\/\/doi.org\/10.1016\/s1367-5931(99)80071-4","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[1999,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets for anti-inflammatory drugs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1367-5931(99)80071-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}